Skip to main
PRCT

PRCT Stock Forecast & Price Target

PRCT Analyst Ratings

Based on 10 analyst ratings
Hold
Strong Buy 10%
Buy 40%
Hold 40%
Sell 10%
Strong Sell 0%

Bulls say

PROCEPT BioRobotics is a promising surgical robotics company with a strong focus on advancing patient care in the urology field. Despite facing challenges such as increased competition from other BPH treatments and reimbursement changes, the company is expected to see steady revenue growth in the coming years, driven by its innovative technology and strong sales initiatives. The company's potential for longer-term growth and current undervaluation compared to its peers make it an attractive investment opportunity for those with a positive outlook on the healthcare sector.

Bears say

PROCEPT BioRobotics is facing headwinds in its growth trajectory due to competition from alternative BPH therapies, which may limit the company's ability to gain market share and drive procedure volumes. In turn, this could lead to lower sales and profitability, impacting the company's financials and ultimately its stock price. The recent sales force reorganization and inventory flush may continue to weigh on the company's performance in the short term. While the company has strong capital placements and high ASPs, there are concerns about the performance of handpiece sales and the steeper second-ramp implied. Additionally, the ongoing prostate cancer study may not have a significant impact on the company's stock in the near future.

PRCT has been analyzed by 10 analysts, with a consensus rating of Hold. 10% of analysts recommend a Strong Buy, 40% recommend Buy, 40% suggest Holding, 10% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PROCEPT BioRobotics Corp (PRCT) Forecast

Analysts have given PRCT a Hold based on their latest research and market trends.

According to 10 analysts, PRCT has a Hold consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PROCEPT BioRobotics Corp (PRCT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.